Trials / Completed
CompletedNCT02265627
Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers
Pharmacokinetics, Safety and Tolerability of Single Dose BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Subjects (An Open Label, Matched Pair, Two Center Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 24 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To investigate the pharmacokinetics of a single dose of BIIL 284 BS in patients with hepatic impairment in comparison to healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIL 284 BS |
Timeline
- Start date
- 2000-03-01
- Primary completion
- 2000-09-01
- First posted
- 2014-10-16
- Last updated
- 2014-10-16
Source: ClinicalTrials.gov record NCT02265627. Inclusion in this directory is not an endorsement.